ADEF
COGT icon

ABS Direct Equity Fund’s Cogent Biosciences COGT Stock Holding History

ABS Direct Equity Fund’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Sell
39
-4,661
-99% -$163K 0.11% 98
2026
Q1 		$173K Buy
+4,700
New +$174K 0.13% 88

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ABS Direct Equity Fund's COGT Position: Q2 2026 in Review

ABS Direct Equity Fund reduced its Cogent Biosciences (COGT) stake by 99% in Q2 2026, selling an estimated $163K and leaving 39 shares worth $182K. The position accounts for 0.11% of the portfolio, ranked #98.

ABS Direct Equity Fund first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • ABS Direct Equity Fund held 39 shares of Cogent Biosciences worth $182K as of Q2 2026.
  • ABS Direct Equity Fund sold 4,661 Cogent Biosciences shares in Q2 2026, an estimated $163K.
  • Cogent Biosciences made up 0.11% of ABS Direct Equity Fund's portfolio in Q2 2026, its #98 holding.
  • ABS Direct Equity Fund first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.